The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.00
Bid: 30.00
Ask: 30.60
Change: 0.65 (2.19%)
Spread: 0.60 (2.00%)
Open: 30.70
High: 30.70
Low: 30.00
Prev. Close: 29.65
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

28 Jun 2023 07:00

RNS Number : 1143E
EKF Diagnostics Holdings PLC
28 June 2023
 

This announcement contains inside informationfor the purposes of UK Market Abuse Regulation.

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Directorate Change

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that Marc Davies is standing down from his role as Chief Financial Officer ("CFO") to pursue other opportunities. Marc will remain in his position to facilitate an orderly handover to his replacement for up to six months, as required.

 

The Company is already in advanced discussions with a suitable candidate for the CFO role, who is experienced in working with AIM-quoted healthcare companies, and is be able to commence the handover process within the next few weeks, with a view to taking on the role permanently in Q4 2023. A further announcement relating to this appointment will be made in due course.

 

Julian Baines remains Executive Chair and is committed to executing the Company's growth strategy, whilst also overseeing the recruitment process for a new Chief Executive Officer. An experienced senior management team continues to support the Executive Chair on an operational level, alongside significant strategic input from the Non-executive Directors.

 

Julian Baines, Executive Chair of EKF, commented: "I would like to thank Marc for his contribution to the Company. We remain confident in the financial condition and robustness of our business and the potential value that EKF offers to shareholders. We have a well-established and growing core business in Point-of Care, and an exciting opportunity in our Life Sciences division over the coming years."

 

The Company expects to give its next scheduled update on H1 trading in late July.

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Oliver Platts

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

 

· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUUCQUPWGRM
Date   Source Headline
4th Mar 20207:00 amRNSNotice of Results
24th Feb 20201:56 pmRNSHolding(s) in Company
29th Jan 20207:00 amRNSTrading update
6th Nov 201912:14 pmRNSTrading update and performance bonuses
10th Sep 20197:00 amRNSHalf-year Report
10th Sep 20197:00 amRNSPreferred Partner Arrangement with Mount Sinai
21st Aug 20197:00 amRNSNotice of Results
8th Aug 20194:40 pmRNSSecond Price Monitoring Extn
8th Aug 20194:35 pmRNSPrice Monitoring Extension
15th Jul 20197:00 amRNSTrading update
11th Jun 20192:15 pmRNSCancellation of share options
7th Jun 20194:30 pmRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 201911:21 amRNSResult of AGM
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
25th Apr 20197:00 amRNSPosting of AR & Accounts and Notice of AGM
13th Mar 20197:00 amRNSFinal Results
8th Mar 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUS FDA approval for Quo-Test analyser
22nd Jan 20197:00 amRNSUpdate on McKesson US distribution agreement
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
16th Jan 20197:00 amRNSTrading update
20th Dec 20187:00 amRNSUpdate regarding planned change of NOMAD
19th Dec 20184:56 pmRNSPDMR dealing
7th Dec 20183:15 pmRNSPurchase of own shares and PDMR Dealing
30th Nov 20182:35 pmRNSTotal Voting Rights
22nd Nov 20185:13 pmRNSPurchase of own shares and PDMR Dealing
21st Nov 20182:08 pmRNSPurchase of own shares and PDMR Dealing
20th Nov 20185:18 pmRNSPurchase of own shares and PDMR Dealing
14th Nov 20182:20 pmRNSShare Buy-Back
9th Nov 20181:48 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings
2nd Nov 20188:00 amRNSSchedule 1 update - Renalytix AI plc
1st Nov 20185:30 pmRNSUpdate regarding AIM admission of RenalytixAI
31st Oct 20186:00 pmRNSResult of RO by RenalytixAI & Fundraising Update
23rd Oct 20182:00 pmRNSSchedule One Update - Renalytix AI plc
23rd Oct 201811:01 amRNSUpdate to distribution timetable
22nd Oct 20185:23 pmRNSApproval of distribution of shares in RenalytixAI
19th Oct 201812:10 pmRNSResult of General Meeting
19th Oct 201811:00 amRNSSchedule One - Renalytix AI plc
12th Oct 20187:00 amRNSInvestor presentation
11th Oct 20186:03 pmRNSLaunch of Restricted Offer by Renalytix AI plc
11th Oct 20185:21 pmRNSFundraising and AIM admission of Renalytix AI plc
11th Oct 20184:01 pmRNSFundraising and AIM admission of Renalytix AI plc
27th Sep 201810:15 amRNSNotice of GM
19th Sep 20187:00 amRNSHalf-year Report
17th Sep 201812:21 pmRNSNotice of Results
31st Aug 20182:00 pmRNSUpdate regarding proposed IPO of Renalytix AI
16th Aug 20187:00 amRNSHolding(s) in Company
9th Aug 20187:14 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.